Table 4. Sensitivity Analyses of Concordance Rates (by Percent Agreement) According to Treatment/Therapeutic Class and to Scan Availability.
| Analysis | No. | % (95% CI) | |||
|---|---|---|---|---|---|
| Best response categories | Dichotomized response, y/n | ||||
| Unconfirmed | Confirmeda | Unconfirmed | Confirmeda | ||
| According to therapy class | |||||
| Anti–VEGF-containing | 27 | 63 (42.4-80.6) | 51.9 (31.9-71.3) | 81.5 (61.9-93.7) | 70.4 (49.8-86.2) |
| Chemotherapy | 35 | 54.3 (36.6-71.2) | 62.9 (44.9-78.5) | 71.4 (53.7-85.4) | 82.9 (66.4-93.4) |
| Targeted | 23 | 65.2 (42.7-83.6) | 43.5 (23.2-65.5) | 78.3 (56.3-92.5) | 56.5 (34.5-76.8) |
| PD-1/PD-L1-based | 15 | 46.7 (21.3-73.4) | 40 (16.3-67.7) | 60 (32.3-83.7) | 66.7 (38.4-88.2) |
| According to scan availability | |||||
| All EHR-documented scans available | 23 | 60.9 (38.5-80.3) | 60.9 (38.5-80.3) | 73.9 (51.6-89.8) | 73.9 (51.6-89.8) |
| At least 1 EHR-documented scan unavailable | 77 | 57.1 (45.4-68.4) | 49.4 (37.8-61) | 74.0 (62.8-83.4) | 70.1 (58.6-80) |
Abbreviations: EHR, electronic health record; PD-(L)1, programmed cell death-(ligand) 1; Targeted therapy, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), and anti-EGFR antibody-based; VEGF, vascular endothelial growth factor.
a
Patients with an initial response, but without subsequent scan to confirm it, would be considered unconfirmed.